New thoughts on the pathobiology of regimen-related mucosal injury
Lowell Anthony1, Joanne Bowen, Adam Garden
1The Stanley S. Scott Cancer Center, LSUHSC, New Orleans, LA, USA.
Background:
Our understanding of the biological basis for mucosal barrier injury (mucositis) induced by cancer therapy with radiation or drugs continues to evolve. A patient's mucosal response to cancer therapy appears to be controlled by both global (i.e. gender, underlying systemic disease, race) and tissue specific (i.e. epithelial type, intrinsic endocrine system, local microbial environment, function) factors.
Conclusion:
Interactions of these elements, coupled with underlying genetic influences, most likely govern the risk, course and severity of regimen-related mucosal injury.
Related Concept Videos
Peptic Ulcer Disease II: Pathophysiology
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Gastritis II: Pathophysiology
Inflammatory Bowel Disease II: Ulcerative Colitis
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

